Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
PP&E Net
Avadel Pharmaceuticals PLC
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
PP&E Net
$3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
PP&E Net
$1.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
PP&E Net
$258.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
12%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
PP&E Net
$620k
|
CAGR 3-Years
84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
PP&E Net
€30.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
PP&E Net
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's PP&E Net?
PP&E Net
3m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's PP&E Net amounts to 3m USD.
What is Avadel Pharmaceuticals PLC's PP&E Net growth rate?
PP&E Net CAGR 10Y
5%
Over the last year, the PP&E Net growth was 26%. The average annual PP&E Net growth rates for Avadel Pharmaceuticals PLC have been 2% over the past three years , -1% over the past five years , and 5% over the past ten years .
